Key clinical point: Patients who have diffuse large B-cell lymphoma with synchronous CNS and systemic disease (synDLBCL) have better outcomes when they receive CNS-directed therapy.
Major finding: The 2-year overall survival rate was 54% in patients who received CNS-intensive therapy and 44% in those who received CNS-conservative therapy (P = .037).
Study details: A retrospective study of 80 patients with synDLBCL.
Disclosures: There was no formal funding for the study. and the researchers did not provide financial disclosures.
Wight JC et al. Br J Haematol. 2019 Jun 24. doi: 10.1111/bjh.16064.